Drug Approval | January 23, 2024
EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Leading USA based genetic testing brand officially enters the Indian market
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Increased capability to produce medicines for challenging diseases including cancer
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Apollo continues to invest in genomics technology and research for better patient care
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Subscribe To Our Newsletter & Stay Updated
